## BMY: Bristol-Myers Squibb Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.4% below STRENGTH zone (3.0-6.0%); PEG 2.26 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($51.77)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. FDA Approves Bristol-Myers Squibb’s Breyanzi as First-Ever CAR T Therapy for Rare Marginal Zone Lymphoma**
- Source: Insider Monkey | 20251221T105700 | Bullish | Relevance: 100%
- The FDA has approved Bristol-Myers Squibb’s Breyanzi (lisocabtagene maraleucel) as the first-ever CAR T cell therapy for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have undergone at least two prior systemic therapies. This approval, based on the TRANSCEND FL study, demonstrated an overall response rate of 95.5% with 62.1% achieving a complete response. Breyanzi is now approved for five distinct types of B-cell malignancies.

**2. FDA Approves Bristol-Myers Squibb’s Breyanzi as First-Ever CAR T Therapy for Rare Marginal Zone Lymphoma**
- Source: Yahoo Finance | 20251221T105700 | Bullish | Relevance: 100%
- The FDA has approved Bristol-Myers Squibb’s Breyanzi (lisocabtagene maraleucel) as the first CAR T cell therapy for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have undergone at least two prior systemic therapies. This approval, based on the TRANSCEND FL study, marks Breyanzi's fifth distinct B-cell malignancy approval, demonstrating a 95.5% overall response rate and deep, durable responses. The therapy, administered as a one-time infusion, has an established safety profile for both inpatient and outpatient settings.

**3. BofA Upgrades Bristol-Myers Squibb (BMY) Stock to Buy from Neutral**
- Source: Insider Monkey | 20251221T104400 | Bullish | Relevance: 100%
- BofA has upgraded Bristol-Myers Squibb (BMY) stock from "Neutral" to "Buy," increasing its price objective to $61 from $52. This upgrade is based on the company's strong R&D pipeline with upcoming de-risking catalysts and a belief that current stock weakness presents a buying opportunity. Additionally, the U.S. FDA has granted priority review for a new sBLA for Opdivo® in combination with AVD for classical Hodgkin Lymphoma.

**4. Bristol-Myers Squibb: Pharma Giant Undervalued, Printing Cash Despite Patent Cliff (BMY)**
- Source: Seeking Alpha | 20251223T163141 | Bullish | Relevance: 100%
- Bristol-Myers Squibb Company has seen a solid rebound as the market reassesses prior negative sentiment. Despite over 60% of its revenue facing potential loss of exclusivity, BMY's growth portfolio expanded by 18% in Q3 and now constitutes over half of its business. The company offers robust free cash flow margins exceeding 30% and a 4.7% dividend yield, making it an attractive investment with an 8.8x forward P/E and a potential 20% upside to $65.

**5. U.S. Capital Wealth Advisors LLC Sells 47,717 Shares of Bristol Myers Squibb Company $BMY**
- Source: MarketBeat | 20251223T105256 | Somewhat-Bullish | Relevance: 100%
- U.S. Capital Wealth Advisors LLC significantly reduced its stake in Bristol Myers Squibb Company by selling 47,717 shares, now owning 28,202 shares valued at $1.272 million. Despite this, analyst sentiment remains mixed with a consensus "Hold" rating and an average price target of $54.62, though Bank of America recently upgraded BMY to a "Buy" with a $61 target. Bristol Myers Squibb also increased its quarterly dividend to $0.63, yielding approximately 4.6%, and provided positive FY2025 EPS guidance after beating recent quarterly estimates.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $61 | $52 | +17% |
| 2025-12-12 | Morgan Stanley | $37 | $36 | +3% |
| 2025-12-12 | Guggenheim | $62 | $0 | 0% |
| 2025-12-10 | Wells Fargo | $55 | $53 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | up | Buy |
| 2025-12-12 | Morgan Stanley | main | Underweight |
| 2025-12-12 | Guggenheim | up | Buy |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 7 ($0.00M) |
| Sells | 3 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.5%)
- Blackrock Inc.: 8.6% (+1.9%)
- JPMORGAN CHASE & CO: 8.5% (+65.8%)
- State Street Corpora: 4.7% (+2.0%)
- Charles Schwab Inves: 3.6% (+3.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 5 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Balance sheet: $6.0B free cash flow. Revenue declining -8% YoY, concerning. Analyst sentiment positive (5 raises, avg +11%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $110.5B |
| Beta | 0.30 |
| 52W Range | $42.52 - $63.33 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 9.1 |
| Current P/E | 8.3 |
| YoY Growth | -8.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 5.2% to 0.4% (-4.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.6pp (needs >3.0% for momentum thesis). MRS_5 (-1.1%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -MLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.43% (CS: 77) | Neutral |
| RSI_14 | 68.2 | Neutral |
| MACD Histogram | 0.13 | Bullish |
| vs SMA20 | 1.048x | Above |
| vs SMA50 | 1.130x | Above |
| vs SMA200 | 1.114x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $54.27
- **Stop Loss:** $51.77 (4.6% risk)
- **Target:** $56.77 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 480
- **Position Value:** $26,049.60
- **Portfolio %:** 26.05%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-05 (Est: $1.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.52 | $1.63 | +7.6% |
| 2025Q2 | $1.10 | $1.46 | +32.6% |
| 2025Q1 | $1.50 | $1.80 | +19.9% |
| 2024Q4 | $1.47 | $1.67 | +13.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*